<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g338" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-336.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
                <a href="#nav-panel" class="ui-btn ui-icon-bars ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-331.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-331.html" >Cervical Cancer Screening for Women Who Attend STD Clinics or Have a History of STDs</a><span class="carrot"> > </span>
                    <a href="lv-336.html" >Special Considerations</a><span class="carrot"> > </span>HIV Infection
            </div>
            </br><h3 class="sgc-1" id="sigil_toc_id_338">
 HIV Infection
</h3>
<p>
 Several studies have documented an increased prevalence of SIL in HIV-infected women (416,436). The following recommendations for Pap test screening among HIV-infected women are consistent with most of the guidelines published by the U.S. Department of Health and Human Services (HHS) (129) and are based partially on the opinions of professionals knowledgeable about the care and management of cervical cancer and HIV infection in women.
</p>
<p>
 HIV-positive women should be provided cervical cytology screening twice (every 6 months) within the first year after initial HIV diagnosis and, if both tests are normal, annual screening can be resumed thereafter. HIV-positive women with ASC-H, LSIL, or HSIL on cytologic screening should undergo colposcopic evaluation. Recommendations for management of HIV-positive women with ASC-US vary. HHS recommends a more conservative management approach (i.e., immediate colposcopy), whereas ASCCP recommends that these women be managed like HIV-negative women with ASC-US (i.e., tested for HR HPV DNA) (424,429).
</p>

            </div>
        <div data-role="panel" data-display="push" data-theme="b" id="nav-panel">
            <ul data-role="listview">
                <li data-icon="delete"><a href="#" data-rel="close">Close menu</a></li>
                <li><a href="../conditions/c0-clv.html">Condition Quick Pick</a></li>
                <li><a href="../guidelines/lv-0.html">Full STD Tx Guidelines</a></li>
                <li><a href="../page/hx-pdf.html">Taking a Sexual Hx PDF</a></li>
                <li><a href="../terms/1.html">Terms and Abbreviations</a></li>
                <li><a href="../refs/lv-0.html">References</a></li>
                <li><a href="../page/about_us.html">About Us</a></li>
            </ul>
        </div><!-- /panel -->
    
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>
    